HN2301 / Shenzhen MagicRNA Biotechnology - LARVOL DELTA

Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs） (clinicaltrials.gov) - P=N/A | N=30 | Recruiting | Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd | Trial completion date: Mar 2026 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis

Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG) (clinicaltrials.gov) - P=N/A | N=9 | Terminated | Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd | Trial completion date: Dec 2026 ➔ Feb 2026 | Initiation date: Jun 2025 ➔ Jan 2026 | Recruiting ➔ Terminated | Trial primary completion date: May 2026 ➔ Feb 2026; Change of registrant

Trial completion date • Trial initiation date • Trial primary completion date • Trial termination • CNS Disorders • Myasthenia Gravis